June 20, 2022
Kyorin Holdings said on June 17 that it has sealed a joint development and license pact for Chiba-based CellGenTech’s genetically modified human adipocytes (GMACs) for the treatment of Fabry disease. Under the deal, Kyorin grabbed the exclusive rights to develop...read more